文献速递哮喘间质性肺疾病

儿童哮喘与囊性纤维化数字生物标志物的临床验证

Clinical validation of digital biomarkers for paediatric patients with asthma and cystic fibrosis: potential for clinical trials and clinical care.
PubMed 文献 · Eur Respir J · 2022-06-09

这项前瞻性队列研究纳入60例哮喘和30例囊性纤维化(CF)患儿(6-16岁),佩戴智能手表、每日居家肺功能及症状问卷28天,并与128名健康儿童比较。结果显示依从性中位数88%,患者体力活动与FEV1低于健康儿童,哮喘患儿心率更高,症状评分高与体力活动低相关,数字生物标志物可描述肺急性加重。

要点

  • 智能手表与便携肺功能仪在儿童哮喘和CF中依从性中位数88%。
  • 患者体力活动与FEV1低于健康儿童,哮喘患儿心率高于健康儿童。
  • 症状加重日体力活动下降、FEV1降低、夜间心率升高,可描述肺急性加重。

核心结论

  • 便携肺功能仪和智能手表衍生的数字生物标志物有望作为儿童肺病临床试验或临床管理的候选终点。

研究设计与样本

  • 前瞻性队列研究,纳入60例哮喘和30例囊性纤维化(CF)患儿(6-16岁),每日居家肺功能28天,并与128名健康儿童比较,采用线性混合效应模型分析。

主要发现

  • 依从性中位数为88%。
  • 患者平均体力活动和FEV1低于健康儿童,而哮喘患儿心率高于健康儿童。
  • 症状评分较高的日子,未控制哮喘和CF患儿体力活动较低。
  • 两组患者症状较多的日子FEV1较低且(夜间)心率较高。
  • 候选生物标志物能够描述肺急性加重。

关键数值与推荐

  • 候选数字终点包括体力活动、心率、睡眠和FEV1。
  • 报告结局包括依从性、患者与对照差异、与疾病活动度的相关性及检测临床事件潜力。

临床怎么用

  • 智能手表和便携肺功能仪可用于儿童哮喘和CF的居家监测,辅助评估疾病活动度和肺急性加重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Digital biomarkers are a promising novel method to capture clinical data in a home setting. However, clinical validation prior to implementation is of vital importance. The aim of this study was to clinically validate physical activity, heart rate, sleep and forced expiratory volume in 1 s (FEV1) as digital biomarkers measured by a smartwatch and portable spirometer in children with asthma and cystic fibrosis (CF). METHODS: This was a prospective cohort study including 60 children with asthma and 30 children with CF (aged 6-16 years). Participants wore a smartwatch, performed daily spirometry at home and completed a daily symptom questionnaire for 28 days. Physical activity, heart rate, sleep and FEV1 were considered candidate digital end-points. Data from 128 healthy children were used for comparison. Reported outcomes were compliance, difference between patients and controls, correlation with disease activity, and potential to detect clinical events. Analysis was performed with linear mixed effects models. RESULTS: Median compliance was 88%. On average, patients exhibited lower physical activity and FEV1 compared with healthy children, whereas the heart rate of children with asthma was higher compared with healthy children. Days with a higher symptom score were associated with lower physical activity for children with uncontrolled asthma and CF. Furthermore, FEV1 was lower and (nocturnal) heart rate was higher for both patient groups on days with more symptoms. Candidate biomarkers appeared able to describe a pulmonary exacerbation. CONCLUSIONS: Portable spirometer- and smartwatch-derived digital biomarkers show promise as candidate end-points for use in clinical trials or clinical care in paediatric lung disease.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Kruizinga, Essers, Stuurman, et al. Clinical validation of digital biomarkers for paediatric patients with asthma and cystic fibrosis: potential for clinical trials and clinical care. Eur Respir J. 2022. PMID: 34887326. doi:10.1183/13993003.00208-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。